Cited 2 times in
Implication of Serious Infections in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the First Cycle of Rituximab: A Pilot Study in a Single Korean Center
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.contributor.author | 송정식 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 표정윤 | - |
dc.contributor.author | 도현수 | - |
dc.date.accessioned | 2023-03-22T02:18:53Z | - |
dc.date.available | 2023-03-22T02:18:53Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 2093-940X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193565 | - |
dc.description.abstract | Objective This study investigated the clinical implications of serious infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) who received the first cycle of rituximab (RTX) during the first 6 months of follow-up. Methods The medical records of 36 AAV patients treated with RTX were reviewed. A weekly dose of 375 mg/m2 RTX was administered for 4 weeks to all patients along with glucocorticoids. Serious infections were defined as those requiring hospitalization. All-cause mortality during the first 6 months of follow-up was counted. The follow-up duration was defined as the period from the first RTX infusion to 6 months after the first RTX infusion. Results The median age was 60.5 years, and 16 patients were male. Seven of 36 patients (19.4%) died and three AAV patients had five cases of serious infection such as enterocolitis, pulmonary aspergillosis, atypical pneumonia, cytomegalovirus pneumonia, and cellulitis. AAV patients with serious infections during the first 6 months of follow-up exhibited a significantly lower cumulative survival rate than those without serious infections (p<0.001). However, we found no independent predictor of serious infections using the Cox hazard model analysis. Conclusion Serious infection is an important predictor of all-cause mortality in Korean patients with AAV who received their first cycle of RTX but there were no significant variables to predict the occurrence of serious infections at the first RTX. Thus, in cases refractory to other induction therapies, RTX should be strongly considered, despite an increase in mortality rate. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | 대한류마티스학회 | - |
dc.relation.isPartOf | Journal of Rheumatic Diseases | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Implication of Serious Infections in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the First Cycle of Rituximab: A Pilot Study in a Single Korean Center | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyunsue Do | - |
dc.contributor.googleauthor | Jung Yoon Pyo | - |
dc.contributor.googleauthor | Jason Jungsik Song | - |
dc.contributor.googleauthor | Yong-Beom Park | - |
dc.contributor.googleauthor | Sang-Won Lee | - |
dc.identifier.doi | 10.4078/jrd.22.0033 | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A02057 | - |
dc.contributor.localId | A02824 | - |
dc.contributor.localId | A04244 | - |
dc.relation.journalcode | J01737 | - |
dc.identifier.eissn | 2233-4718 | - |
dc.subject.keyword | Antineutrophil cytoplasmic antibody | - |
dc.subject.keyword | Vasculitis | - |
dc.subject.keyword | Rituximab | - |
dc.subject.keyword | Infection | - |
dc.subject.keyword | Mortality | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | 박용범 | - |
dc.contributor.affiliatedAuthor | 송정식 | - |
dc.contributor.affiliatedAuthor | 이상원 | - |
dc.contributor.affiliatedAuthor | 표정윤 | - |
dc.citation.volume | 30 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 45 | - |
dc.citation.endPage | 52 | - |
dc.identifier.bibliographicCitation | Journal of Rheumatic Diseases, Vol.30(1) : 45-52, 2023-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.